135 related articles for article (PubMed ID: 26297253)
1. Down-regulation of cytoplasmic PLZF correlates with high tumor grade and tumor aggression in non-small cell lung carcinoma.
Xiao GQ; Li F; Findeis-Hosey J; Hyrien O; Unger PD; Xiao L; Dunne R; Kim ES; Yang Q; McMahon L; Burstein DE
Hum Pathol; 2015 Nov; 46(11):1607-15. PubMed ID: 26297253
[TBL] [Abstract][Full Text] [Related]
2. Loss of PLZF expression in prostate cancer by immunohistochemistry correlates with tumor aggressiveness and metastasis.
Xiao GQ; Unger P; Yang Q; Kinoshita Y; Singh K; McMahon L; Nastiuk K; Sha K; Krolewski J; Burstein D
PLoS One; 2015; 10(3):e0121318. PubMed ID: 25807461
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of TAZ expression in resected non-small cell lung cancer.
Xie M; Zhang L; He CS; Hou JH; Lin SX; Hu ZH; Xu F; Zhao HY
J Thorac Oncol; 2012 May; 7(5):799-807. PubMed ID: 22481233
[TBL] [Abstract][Full Text] [Related]
4. CD44 and its v6 spliced variant in lung carcinomas: relation to NCAM, CEA, EMA and UP1 and prognostic significance.
Nguyen VN; Mirejovský T; Melinová L; Mandys V
Neoplasma; 2000; 47(6):400-8. PubMed ID: 11263866
[TBL] [Abstract][Full Text] [Related]
5. Hypermethylation reduces expression of tumor-suppressor PLZF and regulates proliferation and apoptosis in non-small-cell lung cancers.
Wang X; Wang L; Guo S; Bao Y; Ma Y; Yan F; Xu K; Xu Z; Jin L; Lu D; Xu J; Wang JC
FASEB J; 2013 Oct; 27(10):4194-203. PubMed ID: 23804241
[TBL] [Abstract][Full Text] [Related]
6. An immunohistochemical study of cyclin-dependent kinase 5 (CDK5) expression in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC): a possible prognostic biomarker.
Wei K; Ye Z; Li Z; Dang Y; Chen X; Huang N; Bao C; Gan T; Yang L; Chen G
World J Surg Oncol; 2016 Feb; 14(1):34. PubMed ID: 26860827
[TBL] [Abstract][Full Text] [Related]
7. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
[TBL] [Abstract][Full Text] [Related]
8. [Correlation of P27 expression and localization to phosphorylated AKT in non-small cell lung cancer].
Miao LJ; Wang J; Li SS; Wu YM; Wu YJ; Wang XC
Ai Zheng; 2006 Oct; 25(10):1216-20. PubMed ID: 17059763
[TBL] [Abstract][Full Text] [Related]
9. Co-downregulation of PTEN, KAI-1, and nm23-H1 tumor/metastasis suppressor proteins in non-small cell lung cancer.
Goncharuk VN; del-Rosario A; Kren L; Anwar S; Sheehan CE; Carlson JA; Ross JS
Ann Diagn Pathol; 2004 Feb; 8(1):6-16. PubMed ID: 15129904
[TBL] [Abstract][Full Text] [Related]
10. Frequent down-regulation of pim-1 mRNA expression in non-small cell lung cancer is associated with lymph node metastases.
Warnecke-Eberz U; Bollschweiler E; Drebber U; Pohl A; Baldus SE; Hoelscher AH; Metzger R
Oncol Rep; 2008 Sep; 20(3):619-24. PubMed ID: 18695914
[TBL] [Abstract][Full Text] [Related]
11. [Relationship between expression of caveolin-1 and pERK1/2 and prognosis in non-small cell lung cancer].
Liu HX; Xing LX; Wang HB; Yang JQ; Sun YM
Zhonghua Bing Li Xue Za Zhi; 2008 Sep; 37(9):615-9. PubMed ID: 19094586
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of insulin receptor substrate-I down-regulation in non-small cell lung cancer.
Han CH; Cho JY; Moon JT; Kim HJ; Kim SK; Shin DH; Chang J; Ahn CM; Kim SK; Chang YS
Oncol Rep; 2006 Dec; 16(6):1205-10. PubMed ID: 17089038
[TBL] [Abstract][Full Text] [Related]
13. WWOX expression in different histologic types and subtypes of non-small cell lung cancer.
Donati V; Fontanini G; Dell'Omodarme M; Prati MC; Nuti S; Lucchi M; Mussi A; Fabbri M; Basolo F; Croce CM; Aqeilan RI
Clin Cancer Res; 2007 Feb; 13(3):884-91. PubMed ID: 17289881
[TBL] [Abstract][Full Text] [Related]
14. [Association of HAb18G with clinicopathologic features and prognosis in non-small cell carcinoma of lung].
Xu XY; Zhi C; Li YM; Qi WJ; Mei JJ; Yan ZM; Shen H
Zhonghua Bing Li Xue Za Zhi; 2012 Mar; 41(3):151-5. PubMed ID: 22800476
[TBL] [Abstract][Full Text] [Related]
15. [Over-expression of osteopontin in non-small cell lung cancers: its clinical significance].
Hu Z; Xiao T; Lin DM; Guo SP; Zhang ZQ; Di XB; Cheng SJ; Gao YN
Zhonghua Zhong Liu Za Zhi; 2007 Aug; 29(8):591-5. PubMed ID: 18210878
[TBL] [Abstract][Full Text] [Related]
16. Loss of pRb2/p130 expression is associated with unfavorable clinical outcome in lung cancer.
Caputi M; Groeger AM; Esposito V; De Luca A; Masciullo V; Mancini A; Baldi F; Wolner E; Giordano A
Clin Cancer Res; 2002 Dec; 8(12):3850-6. PubMed ID: 12473599
[TBL] [Abstract][Full Text] [Related]
17. High expression of truncated GLI3 is associated with poor overall survival in patients with non-small cell lung cancer.
Bai XY; Lin JY; Zhang XC; Xie Z; Yan HH; Chen ZH; Xu CR; An SJ; Sheng GM; Wu YL
Cancer Biomark; 2013; 13(1):37-47. PubMed ID: 23736020
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of CD88 predicts poor prognosis in non-small-cell lung cancer.
Gu J; Ding JY; Lu CL; Lin ZW; Chu YW; Zhao GY; Guo J; Ge D
Lung Cancer; 2013 Aug; 81(2):259-65. PubMed ID: 23706417
[TBL] [Abstract][Full Text] [Related]
19. The relationship between RGS5 expression and cancer differentiation and metastasis in non-small cell lung cancer.
Huang G; Song H; Wang R; Han X; Chen L
J Surg Oncol; 2012 Mar; 105(4):420-4. PubMed ID: 21780128
[TBL] [Abstract][Full Text] [Related]
20. Prognostic implications of neuroendocrine differentiation and hormone production in patients with Stage I nonsmall cell lung carcinoma.
Pelosi G; Pasini F; Sonzogni A; Maffini F; Maisonneuve P; Iannucci A; Terzi A; De Manzoni G; Bresaola E; Viale G
Cancer; 2003 May; 97(10):2487-97. PubMed ID: 12733148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
